Hugo combines expertise in neurodegeneration and immunology to help Scitaris clients navigate and capitalize on evolving scientific advances. He began his scientific career with a BSc in Pharmaceutical Sciences at Utrecht University. He then earned an MSc in Neuroscience at the University of Amsterdam and the University of California, San Francisco, where he investigated how sex influences Alzheimer’s disease and how the immune system can be leveraged to modulate tau pathology.

During his PhD at Charité University Berlin, Hugo explored the interplay between microRNAs, Toll-like receptors, and microglia in Alzheimer’s, this work aimed at identifying biomarkers that could lead to more effective, targeted therapies.

At Scitaris, Hugo connects his scientific and translational knowledge to practical applications, delivering innovative solutions in pharma with the goal of making a material impact on both industry and patients.